

Performance in Delivering Clinical Research - Quarter 3 (2017/18)

Note: Chelsea and Westminster Hospital NHS Foundation Trust formally acquired West Middlesex University Hospital NHS Foundation Trust on 01 September 2015, and the submission for the West Middlesex University Hospital NHS Trust has been subsumed into this submission

All hosted, commercial clinical trials closed to recruitment between 01 October -31 December 2017

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
16/LO/0240	199083	An Open-Label, prospective, non-randomized, multicenter study to evaluate clear skin effect on health-related quality of life outcomes at 16 and 52 weeks in patients with moderate to severe plaque psoriasis treated with secukinumab 300 mg	5	5	Date Agreed	26/04/2017	2	26/04/2017	2	Recruitment Finished	Study was a global study with competitive recruitment. Global target was hit before we managed to recruit our local target.
16/EE/0223	201450	A 24-Week, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo <sup>®</sup> and Tresiba <sup>®</sup> in Insulin-Naive Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Oral Antihyperglycemic Agents	4	4	Date Agreed	28/04/2017	0	28/04/2017	0	Withdrawn By Sponsor	Study difficult to recruit to nationally. The changing therapy landscape in type 2 diabetes have pushed insulins further down the pathway hence the paucity of suitable numbers. Sponsor chose to close the study to recruitment nationally. No patients recruited
16/NE/0415	217915	A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, with or without Simeprevir, in Treatment-Naïve Subjects with Genotype 1, 2 or 3 Chronic Hepatitis C infection with or without cirrhosis	5	5	Not Available / Not Agreed		0	31/08/2017	0	Withdrawn By Sponsor	Sponsor discontinued the development of IMP with immediate effect and stopped recruitment on the 31st August 2017 - just 10 days after the Trust confirmed capacity and capability. No patients were recruited in this window.
16/LO/1891	213918	A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepatitis (AH)	1	3	Date Agreed	01/08/2017	1	30/12/2017	1	Recruitment Finished	